An fMRI study examining effects of acute D-cycloserine during symptom provocation in spider phobia

CNS Spectrums

Volumn 14, Issue 10, 2009, Pages 556-571

  Aupperle, Robin L ^a   Hale, Lisa R ^b   Chambers, Rebecca J ^c   Cain, Sharon E ^b   Barth, Frank X ^b   Sharp, Susan C ^b   Denney, Douglas R ^d   Savage, Cary R ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

^d UNIVERSITY OF KANSAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 70849097970     PISSN: 10928529     EISSN: None     Source Type: Journal    
DOI: 10.1017/S1092852900024044     Document Type: Article

References (74)

1. Kessler RC, Chiu WT, Demler O, Merikangas KR, Walters EE. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005;62:617-627. (Pubitemid 40973437)
2. Black DW. Efficacy of combined pharmacotherapy and psychotherapy versus monotherapy in the treatment of anxiety disorders. CNS Spectr. 2006;11(Suppl 12):29-33.
3. Hofmann SG, Smits JA. Cognitive-behavioral therapy for adult anxiety disorders: a meta-analysis of randomized placebo-controlled trials. J Clin Psychiatry. 2008;69:621-632.
4. Foa EB, Franklin ME, Moser J. Context in the clinic: how well do cognitive-behavioral therapies and medications work in combination? Biol Psychiatry. 2002;52:987-997. (Pubitemid 35356356)
5. Walker DL, Ressler KJ, Lu K, Davis M. Facilitation of conditioned fear extinction by systematic administration or intra-amygdala infusions of D-cycloserine as assessed with fear-potentiated startle in rats. J Neurosci. 2002;22:2343-2351. (Pubitemid 35386533)
6. Ledgerwood L, Richardson R, Cranney J. Effects of D-cycloserine on extinction of conditioned freezing. Behav Neurosci. 2003;11:341-349.
7. Ledgerwood L, Richardson R, Cranney J. D-cycloserine facilitates extinction of learned fear: Effects on reacquisition and generalized extinction. Biol Psychiatry. 2005;57:841-847. (Pubitemid 40488352)
8. Ledgerwood L, Richardson R, Cranney J. D-cycloserine and the facilitation of conditioned fear: Consequences of reinstatement. Behav Neurosci. 2004;118:505-513. (Pubitemid 38685318)
9. Watson GB, Bolanowski MA, Baganoff MP, Deppeler CL, Lanthorn TH. D-cycloserine acts as a partial agonist at the glycine modulatory site of the NMDA receptor expressed in Xenopus oocytes. Brain Res. 1990;510:158-160.
10. Bliss TV, Collingridge GL. A synaptic model of memory: long-term potentiation in the hippocampus. Nature. 1993; 361:31-39. (Pubitemid 23020772)
11. Malenka RC, Nicoll RA. NMDA-receptor-dependent synaptic plasticity: multiple forms and mechanisms. Trends Neurosci. 1993;16:521-527. (Pubitemid 23341961)
12. Sakurai S, Yu L, Tan SE. Roles of hippocampal N-methyl-D-aspartate receptors and calcium/calmodulin-dependent protein kinase II in amphetamine-produced conditioned place preference in rats. Behav Pharmacol. 2007;18:497-506.
13. Rouaud E, Billard JM. D-cycloserine facilitates synaptic plasticity but impairs glutamatergic neurotransmission in rat hippocampal slices. Br J Pharmacol. 2003;140:1051-1056. (Pubitemid 37475971)
14. Wu SL, Hsu LS, Tu WT, et al. Effects of D-cycloserine on the behavior and ERK activity in the amygdala: role of individual anxiety levels. Behav Brain Res. 2008;187:246-253.
15. Fujihira T, Kanematsu S, Umino A, Yamamoto N, Nishikawa T. Selective increase in the extracellular D-serine contents by D-cycloserine in the rat medial frontal cortex. Neurochem Int. 2007;51:233-236. (Pubitemid 47176710)
16. Ressler KJ, Rothbaum BO, Tannenbaum L, et al. Cognitive enhancers as adjuncts to psychotherapy. Arch Gen Psychiatry. 2004;61:1136-1144.
17. Hofmann SG, Meuret AE, Smits JA, et al. Augmentation of exposure therapy with D-cycloserine for social anxiety disorder. Arch Gen Psychiatry. 2006;63:298-304. (Pubitemid 43345354)
18. Guastella AJ, Richardson R, Lovibond PF, et al. A randomized controlled trial of D-cycloserine enhancement of exposure therapy for social anxiety disorder. Biol Psychiatry. 2008;63:544-549.
19. Kushner MG, Kim SW, Donahue C, et al.. D-cycloserine augmented exposure therapy for obsessive-compulsive disorder. Biol Psychiatry. 2007;62:835-838. (Pubitemid 47488217)
20. Wilhelm S, Buhlmann U, Tolin DF, et al. Augmentation of behavior therapy with d-cycloserine for obsessive-compulsive disorder. Am J Psychiatry. 2008;65:335-341.
21. Storch EA, Merlo LJ, Bengtson M, et al. D-cycloserine does not enhance exposure- response prevention therapy in obsessive-compulsive disorder. Int Clin Psychopharmacol. 2007;22:230-237. (Pubitemid 46801947)
22. Rothbaum BO. Critical parameters for D-cycloserine enhancement of cognitive-behaviorial therapy for obsessive-compulsive disorder. Am J Psychiatry. 2008;165:293-296.
23. Britton JC, Gold AL, Feczko EJ, Rauch SL, Williams D, Wright CI. D-cycloserine inhibits amygdala responses during repeated presentations of faces. CNS Spectr. 2007;12:600-605. (Pubitemid 47329496)
24. Kalisch R, Holt B, Petrovic P, et al. The NMDA Agonist D-Cycloserine Facilitates Fear Memory Consolidation in Humans. Cereb Cortex. 2009;19:187-196.
25. Maren S. Building and burying fear memories in the brain. Neuroscientist. 2005;11:89-99. (Pubitemid 40223093)
26. Norberg MM, Krystal JH, Tolin DF. A meta-analysis of D-cycloserine and the facilitation of fear extinction and exposure therapy. Biol Psychiatry. 2008;63:1118-1126.
27. Brown TA, DiNardo P, Barlow DH. Anxiety Disorders Interview Schedule for DSM IV (ADIS-IV). New York, NY: Oxford University Press; 1994.
28. Klorman R, Hastings JE, Weerts TC, Melamed BG, Lang PJ. Psychometric Description of Some Specific-Fear Questionnaires. Behav Therapy. 1974;5:401-409.
29. Beck AT, Steer RA, Brown GK. Manual for the Beck Depression Inventory-II. San Antonio, TX: Psychological Corporation; 1996.
30. Wechsler D. Wechsler adult intelligence scale, third edition (WAIS-III) administration and scoring manual. San Antonio, TX: Psychological Corporation; 1997.
31. Merckelbach H, Jong P, Arntz A. Case history and shorter communication: Imagery ability and exposure in vivo in spider phobia. Behav Res Ther. 1991;29:203-205.
32. D'Souza DC, Gil R, Cassello K, et al. IV Glycine and oral D-cycloserine effects on plasma and CSF amino acids in healthy humans. Biol Psychiatry. 2000;47:450-462. (Pubitemid 30110616)
33. Baron H, Epstein IG, Mulinos MG, Nair KG. Absorption, distribution, and excretion of cycloserine in man. Antiobiot Annu. 1956;3:136-140.
34. Straube T, Glauer M, Dilger S, Mentzel H, Miltner W. Effects of cognitive-behavioral therapy on brain activation in specific phobia. NeuroImage. 2006;29:125-135. (Pubitemid 41828037)
35. Lang PJ, Bradley M, Cuthbert B. The International Affective Picture System: Technical Manual and Affective Ratings. Gainesville, FL: The Center for Research in Psychophysiology, University of Florida; 1999.
36. Pissiota A, Frans O, Michelgård A, et al. Amygdala and anterior cingulate cortex activation during affective startle modulation: a PET study of fear. Eur J Neurosci. 2003;18:1325-1331.
37. Goebel R, Jansma H. Brain voyager QX, version 2.0. Brain Innovation BV; 2004.
38. Talairach J., Tournoux P. Co-planar Steriotaxic Atlas of the Human Brain. New York, NY: Thieme Medical Publishers ;1988.
39. Kim H, Somerville LH, Johnstone T, Alexander AL, Whalen PJ. Inverse amygdala and medial prefrontal cortex responses to surprised faces. Neuroreport. 2003;14:2317-2322.
40. McNally RJ. Mechanisms of exposure therapy: how neuroscience can improve psychological treatments for anxiety disorders. Clin Psychol Rev. 2007;27:750-759.
41. Shin LM, Orr SP, Carson MA, et al. Regional cerebral blood flow in the amygdala and medial prefrontal cortex during traumatic imagery in male and female Vietnam veterans with PTSD. Arch Gen Psychiatry. 2004;61:168-176.
42. Shin LM, Wright CI, Cannistraro PA, et al. A functional magnetic resonance imaging study of amygdala and medial prefrontal cortex responses to overtly presented fearful faces in posttraumatic stress disorder. Arch Gen Psychiatry. 2005;62:273-281.
43. SPSS Inc. SPSS Base 8.0 for Windows User's Guide. Chicago, IL: SPSS Inc.; 1998.
44. Friston KJ, Holmes AP, Worsley K, Poline JB, Frith C, Frackowiak RS. Statistical parametric maps in functional imaging: A general linear approach. Hum Brain Map. 1995;2:189-210. (Pubitemid 124008664)
45. Hajnal JV, Myers R, Oatridge A, Schwieso JE, Young IR, Bydder GM. Artifacts due to stimulus correlated motion in functional imaging of the brain. Magn Reson Med. 1994;31:283-291. (Pubitemid 24070943)
46. Morgan VL, Dawant BM, Li Y, Pickens DR. Comparison of fMRI statistical software packages and strategies for analysis of images containing random and stimulus-correlated motion. Comput Med Imaging Graph. 2007;31:436-446. (Pubitemid 47043383)
47. Paquette V, Levesque J, Morson B, Leroux JM, Beaudoin G, Bourgouin P. Change the mind and you change the brain: Effects of cognitive behavioral therapy on the neural correlates of spider phobia. NeuroImage. 2003;18:401-409. (Pubitemid 36269149)
48. Schienle A, Schäfer A, Hermann A, Rohrmann S, Vaitl D. Symptom provocation and reduction in patients suffering from spider phobia: an fMRI study on exposure therapy. Eur Arch Psychiatry Clin Neurosci. 2007;257:486-493. (Pubitemid 351208373)
49. Straube T, Mentzel HJ, Miltner WH. Waiting for spiders: brain activation during anticipatory anxiety in spider phobics. Neuroimage. 2007;37:1427-1436. (Pubitemid 47385286)
50. Millecamps M, Centeno MV, Berra HH, et al. D-cycloserine reduces neuropathic pain behavior through limbic NMDA-mediated circuitry. Pain. 2007;132:108-123. (Pubitemid 47494564)
51. Murai R, Noda Y, Matsui K, et al. Hypofunctional glutamatergic neurotransmission in the prefrontal cortex is involved in the emotional deficit induced by repeated treatment with phencyclidine in mice: implications for abnormalities of glutamate release and NMDA-CaMKII signaling. Behav Brain Res. 2007;180:152-160. (Pubitemid 46719421)
52. Kalisch R, Korenfeld E, Stephan KE, Weiskopf N, Seymour B, Dolan RJ. Context-dependent human extinction memory is mediated by a ventromedial prefrontal and hippocampal network. J Neurosci. 2006;26:9503-9511. (Pubitemid 44396863)
53. Kalisch R, Wiech K, Critchley HD, et al. Anxiety reduction through detachment: subjective, physiological, and neural effects. J Cogn Neurosci. 2005;17:874-883. (Pubitemid 40800021)
54. Milad MR, Rauch SL. The role of the orbitofrontal cortex in anxiety disorders. Ann N Y Acad Sci. 2007;1121:546-561.
55. Critchley HD. Neural mechanisms of autonomic, affective, and cognitive integration. J Comp Neurol. 2005;493:154-166. (Pubitemid 41636198)
56. Phillips ML, Drevets WC, Rauch SL, Lane R. Neurobiology of emotion perception I: The neural basis of normal emotion perception. Biol Psychiatry. 2003;54:504-514. (Pubitemid 37289437)
57. Paulus MP, Stein MB. An insular view of anxiety. Biol Psychiatry. 2006;60:383-387.
58. Simmons A, Matthews SC, Paulus MP, Stein MB. Intolerance of uncertainty correlates with insula activation during affective ambiguity. Neurosci Lett. 2008;430:92-97.
59. Stein MB, Simmons AN, Feinstein JS, Paulus MP. Increased amygdala and insula activation during emotion processing in anxiety-prone subjects. Am J Psychiatry. 2007;164:318-327 (Pubitemid 46318571)
60. Dilger S, Straube T, Mentzel HJ, et al. Brain activation to phobia-related pictures in spider phobic humans: an event-related fMRI study. Neurosci Lett. 2003;348:29-32.
61. Goossens L, Sunaert S, Peeters R, Griez EJ, Schruers KR. Amygdala hyperfunction in phobic fear normalizes after exposure. Biol Psychiatry. 2007;62:1119-1125. (Pubitemid 350029725)
62. Cechetto DF. Identification of a cortical site for stress-induced cardiovascular dysfunction. Integr Physiol Behav Sci. 1994;29:362-373.
63. Craig AD. How do you feel? Interoception: the sense of the physiological condition of the body. Nat Rev Neurosci. 2002;3:655-666.
64. Foa EB, Kozak MJ. Emotional processing of fear: Exposure to corrective information. Psychol Bull. 1986;99:20-35.
65. Lang PJ. Imagery in therapy: An information processing analysis of fear. Behav Ther. 1977;8:862-886. (Pubitemid 8243450)
66. Lang PJ. A bio-informational theory of emotional imagery. Psychophysiology. 1979;16:495-512.
67. Rodebaugh TL, Chambless DL. Cognitive therapy for performance anxiety. J Clin Psychol. 2004;60:809-820.
68. Davis M, Myers KM, Chhatwal J, Ressler KJ. Pharmacological treatments that facilitate extinction of fear: relevance to psychotherapy. NeuroRx. 2006;3:82-96. (Pubitemid 43276635)
69. Bush G, Luu P, Posner MI. Cognitive and emotional influences in anterior cingulate cortex. Trends Cogn Sci. 2000;4:215-222. (Pubitemid 30332147)
70. Yaka R, Biegon A, Grigoriadis N, et al. D-cycloserine improves functional recovery and reinstates long-term potentiation (LTP) in a mouse model of closed head injury. FASEB J. 2007;21:2033-2041. (Pubitemid 47026439)
71. Yang YL, Lu KT. Facilitation of conditioned fear extinction by D-cycloserine is mediated by mitogen-activated protein kinase and phosphatidylinositol 3-kinase cascades and requires de novo protein synthesis in basolateral nucleus of amygdala. Neuroscience. 2005;134:247-260.
72. Yamamoto S, Morinobu S, Fuchikami M, Kurata A, Kozuru T, Yamawaki S. Effects of Single Prolonged Stress and D-Cycloserine on Contextual Fear Extinction and Hippocampal NMDA Receptor Expression in a Rat Model of PTSD. Neuropsychopharmacology. 2008;33:2108-2116. (Pubitemid 351992081)
73. Kim H, Somerville LH, Johnstone T, Polis S, Alexander AL, Shin LM, Whalen PJ. Contextual modulation of amygdala responsivity to surprised faces. J Cogn Neurosci. 2004;16:1730-1745 (Pubitemid 40052455)
74. Tsukada H, Kakiuchi T, Shizuno H, Nishiyama S. Interactions of cholinergic and glutamatergic neuronal systems in the functional activation of cerebral blood flow response: a PET study in unanesthetized monkeys. Brain Res. 1998;796:82-90.